澳大利亚联邦政府提议修改“研发税收激励”计划,旨在到2030年节省5.9亿澳元 1。该提案包括对成立超过10年的小企业取消可退还的税收抵免(治疗性商品公司为15年),并禁止间接支持研发的活动申报抵免 1。法案已在众议院通过,即将提交参议院表决,若获通过将自2028年6月1日起生效 1。
绿党表示除非限制大型石油和天然气生产商每年获得数亿美元的税收抵免,否则不会支持该变革 1。部分澳洲生命科学公司称若变革通过,其税收抵免可能减少高达60% 1。
The Australian federal government has proposed significant changes to its research and development (R&D) tax incentive scheme, aiming to save $590 million by 2030. 1 These reforms have already passed the House of Representatives in late October and are now pending a vote in the Senate, with implementation scheduled to begin on June 1, 2028, should they be approved. 1 The current scheme resulted in a $4.3 billion revenue loss for the federal budget during the 2024-25 fiscal year. 1
Under the new guidelines, small businesses operating for more than 10 years would lose eligibility for refundable tax offsets, although companies developing therapeutic goods would retain this benefit for up to 15 years. 1 Additionally, the turnover threshold required to access the highest offset rates will increase from over $20 million to over $50 million, and activities indirectly supporting R&D will no longer be eligible for claims. 1 Some Australian life sciences firms have warned that if these changes proceed, their tax offsets could decrease by as much as 60%. 1
Political support for the bill remains conditional, with the Greens stating they will not back the reforms unless major oil and gas producers are prevented from claiming hundreds of millions of dollars in annual tax offsets. 1
评论
还没有评论,欢迎留下第一条。